Rizwan Danish, MD
Hematology & Oncology · Flint, MINPI 1720076284
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $35,760 of the $43,483 with a category attached, or 82.2%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among hematology & oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,964 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- AstraZeneca$2K
- Johnson & Johnson$2K
- Genentech USA, Inc.$2K
- Merck$2K
- Pfizer$1K
- plus $26K from 54 others
Across 32 payments — averaging $179.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$6K
What the payments were for
- Consulting fees$1,5504%
- Food & beverage$35,76082%
- Education$1,8574%
- Gifts$1,1363%
- Other$3,1807%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,483 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 180 | $2,752,208 |
| PomalystPomalidomide | 51 | $1,244,870 |
| CalquenceAcalabrutinib Maleate | 72 | $1,110,304 |
| JakafiRuxolitinib Phosphate | 57 | $958,890 |
| XtandiEnzalutamide | 61 | $854,167 |
| KisqaliRibociclib Succinate | 48 | $769,603 |
| RevlimidLenalidomide | 45 | $645,999 |
| PromactaEltrombopag Olamine | 32 | $599,292 |
| DopteletAvatrombopag Maleate | 40 | $450,512 |
| Lenalidomide | 33 | $400,142 |
| NeulastaPegfilgrastim | 51 | $318,215 |
| VenclextaVenetoclax | 28 | $280,998 |
| ImbruvicaIbrutinib | 14 | $242,494 |
| IbrancePalbociclib | 16 | $236,284 |
| SprycelDasatinib | 26 | $234,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $2,031 | $2,787,622206 claims |
| NovartisKisqali, Promacta, Mekinist, Tafinlar | $6,196 | $1,754,365106 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $818 | $1,479,47777 claims |
| AstraZenecaCalquence | $2,138 | $1,110,30472 claims |
| Incyte CorporationJakafi | $853 | $958,89057 claims |
| Astellas Pharma US IncXtandi | $1,156 | $854,16761 claims |
| Bristol Myers SquibbRevlimid | $737 | $645,99945 claims |
| Dova PharmaceuticalsDoptelet | $176 | $450,51240 claims |
| PfizerIbrance, Eliquis | $1,385 | $376,188151 claims |
| AmgenNeulasta | $1,218 | $318,21551 claims |
| AbbVieVenclexta | $729 | $280,99828 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $362 | $242,49414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Flint
- Madan AroraFlint$84K
- T SinghFlint$9K
- Alyssa KipkeFlint$8K
- Venkatasiva PeramFlint$8K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.